T1	And 32 36	with
E1	And:T1 
T2	Procedure 37 43	biopsy
E2	Procedure:T2 Name:T31
T3	Modifier 51 90	metastatic cervical nodal squamous cell
E3	Modifier:T3 
T4	Condition 91 100	carcinoma
E4	Condition:T4 
T5	Procedure 106 108	CT
E5	Procedure:T5 Name:T33
T6	Modifier 116 120	neck
E6	Modifier:T6 
T7	And 121 125	with
E7	And:T7 
T8	Negation 145 148	not
E8	Negation:T8 
T9	Eq-Comparison 215 222	Planned
E9	Eq-Comparison:T9 Temporal-Period:T34
T10	Procedure 244 251	FDG PET
E10	Procedure:T10 
T11	Procedure 252 266	CT examination
E11	Procedure:T11 
T12	Eq-Comparison 272 279	Planned
E12	Eq-Comparison:T12 Temporal-Period:T36
T13	Procedure 292 301	care exam
E13	Procedure:T13 
T14	Procedure 308 318	anesthesia
E14	Procedure:T14 Name:T37
T15	Procedure 324 353	oropharyngeal surgical biopsy
E15	Procedure:T15 Name:T38
T16	Condition 379 387	Pregnant
E16	Condition:T16 Name:T39
T17	Allergy 405 412	allergy
E17	Allergy:T17 
T18	Drug 416 419	FDG
E18	Drug:T18 Name:T41
T19	Drug 421 433	fluciclovine
E19	Drug:T19 Name:T42
T20	Or 435 437	or
E20	Or:T20 
T21	Drug 438 444	iodine
E21	Drug:T21 Name:T43
T22	Drug 460 466	agents
E22	Drug:T22 Name:T45
T23	Condition 479 496	renal dysfunction
E23	Condition:T23 Name:T47
T24	Observation 498 522	glomerular filtrate rate
E24	Observation:T24 Name:T48
T25	Eq-Comparison 524 538	within 30 days
E25	Eq-Comparison:T25 Operator:T49 Value:T50 Temporal-Unit:T51
T26	Eq-Comparison 540 552	less than 30
E26	Eq-Comparison:T26 Operator:T52 Value:T53
T27	Condition 559 593	Inability to tolerate lying supine
E27	Condition:T27 Name:T54
T28	Condition 595 616	relatively motionless
E28	Condition:T28 
T29	Eq-Comparison 621 633	up to 1 hour
E29	Eq-Comparison:T29 Value:T55 Temporal-Unit:T56
T30	Life-Stage-And-Gender 25 31	Adults
A1	Life-Stage-And-Gender-Type T30 adult
T31	Procedure-Name 37 43	biopsy
T32	Condition-Name 77 100	squamous cell carcinoma
T33	Procedure-Name 106 108	CT
T34	Eq-Temporal-Period 215 222	Planned
A2	Eq-Temporal-Period-Value T34 future
T35	Procedure-Name 244 266	FDG PET CT examination
T36	Eq-Temporal-Period 272 279	Planned
A3	Eq-Temporal-Period-Value T36 future
T37	Procedure-Name 308 318	anesthesia
T38	Procedure-Name 324 353	oropharyngeal surgical biopsy
T39	Condition-Name 379 387	Pregnant
T40	Life-Stage-And-Gender 388 393	women
A4	Life-Stage-And-Gender-Type T40 female
T41	Drug-Name 416 419	FDG
T42	Drug-Name 421 433	fluciclovine
T43	Drug-Name 438 444	iodine
T44	Polarity 451 459	contrast
A5	Polarity-Value T44 negative
T45	Drug-Name 460 466	agents
T46	Severity 472 478	Severe
A6	Severity-Value T46 severe
T47	Condition-Name 479 496	renal dysfunction
T48	Observation-Name 498 522	glomerular filtrate rate
A7	Observation-Type-Value T48 lab
T49	Eq-Operator 524 530	within
A8	Eq-Operator-Value T49 LTEQ
T50	Eq-Value 531 533	30
T51	Eq-Temporal-Unit 534 538	days
A9	Eq-Temporal-Unit-Value T51 day
T52	Eq-Operator 540 549	less than
A10	Eq-Operator-Value T52 LT
T53	Eq-Value 550 552	30
T54	Condition-Name 572 593	tolerate lying supine
T55	Eq-Value 627 628	1
T56	Eq-Temporal-Unit 629 633	hour
A11	Eq-Temporal-Unit-Value T56 hour
